Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES

Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES

Background: Patients with recent acute coronary syndrome (ACS) commonly experience chest pain, which affects quality of life even when not due to recurrence of ACS. This post hoc analysis of ODYSSEY OUTCOMES assessed the effect of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor...

Full description

Bibliographic Details
Main Authors: Gregory P. Geba, Ruifeng Chen, Kasturi Talapatra, Taylor Brackin, Kusha A. Mohammadi, Robert Pordy, Garen Manvelian, David J. Maron, Gregory G. Schwartz, Michael Szarek, Ph. Gabriel Steg, Sergio Fazio
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:American Journal of Preventive Cardiology
Subjects:
Acute coronary syndrome
Alirocumab
Cardiovascular disease
Chest pain
Proprotein convertase subtilisin/kexin type 9
Low-density lipoprotein cholesterol
Online Access:http://www.sciencedirect.com/science/article/pii/S2666667724002691

Internet

http://www.sciencedirect.com/science/article/pii/S2666667724002691

Similar Items